A Multi-center, Open-label, Uncontrolled, Single-arm, Extension Study to Determine the Long-term Safety and Tolerability of Oral Lucerastat in Adult Subjects With Fabry Disease
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Lucerastat (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Registrational
- Sponsors Idorsia Pharmaceuticals
- 24 Jan 2019 Planned primary completion date changed from 15 Feb 2022 to 15 Jan 2022.
- 22 Jan 2019 Status changed from not yet recruiting to recruiting.
- 18 Dec 2018 Planned initiation date changed from 15 Dec 2018 to 31 Dec 2018.